| Literature DB >> 26497904 |
Andrew E Epstein1, Brian Olshansky2, Gerald V Naccarelli3, John I Kennedy4, Elizabeth J Murphy5, Nora Goldschlager6.
Abstract
Amiodarone, an iodinated benzofuran derivative with Class I, II, III, and IV antiarrhythmic properties, is the most commonly used antiarrhythmic drug used to treat supraventricular and ventricular arrhythmias. Appropriate use of this drug, with its severe and potentially life-threatening adverse effects, requires an essential understanding of its risk-benefit properties in order to ensure safety. The objective of this review is to afford clinicians who treat patients receiving amiodarone an appropriate management strategy for its safe use. The authors of this consensus management guide have thoroughly reviewed and evaluated the existing literature on amiodarone and apply this information, along with the collective experience of the authors, in its development. Provided are management guides on the intravenous and oral dosing of amiodarone, appropriate outpatient follow-up of patients taking the drug, its recognized adverse effects, and recommendations on when to consult specialists to help in patient management. All clinicians must be cognizant of the appropriate use, follow-up, and adverse reactions of amiodarone. The responsibility incurred by those treating such patients cannot be overemphasized. Published by Elsevier Inc.Entities:
Keywords: Adverse drug reactions; Amiodarone; Atrial fibrillation; Ventricular fibrillation; Ventricular tachycardia
Mesh:
Substances:
Year: 2015 PMID: 26497904 DOI: 10.1016/j.amjmed.2015.08.039
Source DB: PubMed Journal: Am J Med ISSN: 0002-9343 Impact factor: 4.965